Published on January 27, 2010 at 7:09 AM
Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the
development of innovative therapies for the brain and central nervous
system, announced that the U.S. Patent and Trademark Office (US PTO) has
expanded the intellectual property protections enabled by a previously
issued patent that is central to Neurologix’s Parkinson’s disease
program. The new allowances to U.S. Patent Number 765,446, entitled
“Glutamic acid decarboxylase (GAD) based delivery systems,” broaden the
patent’s coverage beyond Parkinson’s disease to include the use of GAD65
in the treatment of other neurological and related disorders.
“The covered technology is not only at the core of
our Parkinson’s disease program, of which Phase 2 initial efficacy
results are expected to be announced in mid-2010, but has potential
application to other important diseases within our company’s core
therapeutic focus.”
“This broadened coverage for Neurologix’s intellectual property in the
field of gene-based medicine for brain and CNS diseases further
reinforces our leadership position as an innovator in this emerging
therapeutic modality,” said John Mordock, Neurologix President and Chief
Executive Officer. “The covered technology is not only at the core of
our Parkinson’s disease program, of which Phase 2 initial efficacy
results are expected to be announced in mid-2010, but has potential
application to other important diseases within our company’s core
therapeutic focus.”
SOURCE Neurologix, Inc.